Benefiting from the most efficient or adapted therapy to cure from disease and/or to be cured with the best quality of life during treatment
Providing innovative and non-invasive Blood-based In Vitro Diagnostic to predict patient response to a certain therapy
CLINICS & HOSPITALS
Making a diagnosis, treating, providing medical follow-up with the objective to personalize patient’s medical care in taking into account individual differences
The first diagnostic to predict the patient response in pancreatic cancer treatment
A rare and “silent” disease with no symptom early on, difficult to diagnose and cure.
A blood-based molecular test (RUO diagnostic) to predict patient’s therapeutic response
The less toxic and expensive chemotherapy in pancreatic cancer treatment
A combination of biomarkers to identify patients most likely to benefit from gemcitabine
Prescribing the right treatment to the right patient requires funds.
To financially support ACOBIOM’s developments, please visit the “Fundraising” page
Acobiom is an innovative biotechnology company specialized in the discovery of new biomarkers and in the development of innovative diagnostics.
Analyses of biological phenotypes; investigation of gene expression changes; Identification & validation of acid nucleic (DNA, RNA, miRNA, small RNA, coding & non coding RNA) biomarkers based on Sequencing/NGS & PCR technologies.
Treatments & analyses of sequencing/omics big data through a proprietary suite of Bioinformatic and Biostatistic tools; Development of a 21,000 Human RNA-Seq database, in-silico investigations through public & proprietary databases.
Biomarkers and diagnostics “to optimize a specific preventive, diagnostic or therapeutic intervention in a given subpopulation of patients, which would most likely to benefit from it”.
A unique scientific and technical expertise associated with 20-year experience in genomics & transcriptomics, in sequencing/NGS & PCR technologies, in performing RNA-Seq / ChIP-seq analyses, and PCR / qPCR / qRT-PCR experiences.
Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
• CE marked test for patients with pancreatic ductal adenocarcinoma
• Prediction of response to first-line gemcitabine-based chemotherapy
• Developed and validated with real world data and samples
Dr. Noelle LoConte (MD, University of Wisconsin) presents the predictive performance of GemciTest®
Pancreatic cancer is a highly lethal cancer. For several years, gemcitabine has been one of the main chemotherapies used to treat this cancer. But there is no routine biomarker to predict its efficacy.
Dr. Noelle LoConte presented the results of using GemciTest® in a confirmatory study, which shows the predictive performance of this in-vitro diagnostic based on PCR technology and a blood RNA signature.
ACOBIOM obtains the hi-France label from AFPC
The French Association of Competitiveness Poles (FACP) awards ACOBIOM the hi-France label, the label of innovative companies to invest in.Read more
Since its foundation, Acobiom has always been at the forefront of Medical Innovation.
Acobiom was founded by Didier Ritter and Dr David Piquemal under the name « Skuldtech » to promote the gene expression profile (transcriptome) approach with the objective to discover RNA biomarkers, to develop diagnostics, and to improve the patient’s medical care.FOR MORE INFORMATION